#152591

Anti-TACE [D1 (A12)] (mouse IgG)

Cat. #152591

Anti-TACE [D1 (A12)] (mouse IgG)

Cat. #: 152591

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: TACE (ADAM17)

Class: Recombinant

Application: Fn

Reactivity: Human

Host: Mouse

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Gillian Murphy ; Christopher Tape

Institute: Absolute Antibody ; Cancer Research UK Cambridge Institute

Tool Details
Target Details
Applications
Handling
Related Tools
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-TACE [D1 (A12)] (mouse IgG)
  • Clone: rD1 (A12)
  • Tool sub type: Primary antibody
  • Class: Recombinant
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: Fn
  • Description: TACE (CD156b) has proved capable of cleaving epidermal growth factor receptor (EGFR) ligands, extracellular Notch1, cell-surface receptors, and adhesion molecules. As proteolytic cleavage is an indispensable activation event for many of these substrates, TACE has emerged as an attractive therapeutic target for the treatment of cancer and rheumatoid arthritis. This “cross-domain” human antibody is a selective TACE antagonist and provides a unique alternative to smallmole...
  • Immunogen: Recombinant human ADAM17 (TACE) ectodomain tagged to biotin.
  • Isotype: IgG1
  • Recommended controls: Brain, heart, kidney, liver, lung and spleen

Target Details

  • Target: TACE (ADAM17)
  • Tissue cell line specificity: Brain, heart, kidney, liver, lung and spleen
  • Target background: TACE (CD156b) has proved capable of cleaving epidermal growth factor receptor (EGFR) ligands, extracellular Notch1, cell-surface receptors, and adhesion molecules. As proteolytic cleavage is an indispensable activation event for many of these substrates, TACE has emerged as an attractive therapeutic target for the treatment of cancer and rheumatoid arthritis. This cross-domain human antibody is a selective TACE antagonist and provides a unique alternative to smallmolecule met...

Applications

  • Application: Fn

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS only
  • Storage conditions: -20° C
  • Shipping conditions: Shipping at 4° C

Related Tools

  • Related tools: Anti-TACE, Recombinant [D1 (A12)]

References

  • Original antibody first published in Tape et al. 2011. Proc Natl Acad Sci U S A. 108(14):5578-83. PMID: 21415364.
  • Cross-domain inhibition of TACE ectodomain.